| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4644857
Max Phase: Preclinical
Molecular Formula: C22H22ClN3O3
Molecular Weight: 411.89
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COc1ccc(OCC2c3cnn(C)c3CCN2C(=O)c2cccc(Cl)c2)cc1
Standard InChI: InChI=1S/C22H22ClN3O3/c1-25-20-10-11-26(22(27)15-4-3-5-16(23)12-15)21(19(20)13-24-25)14-29-18-8-6-17(28-2)7-9-18/h3-9,12-13,21H,10-11,14H2,1-2H3
Standard InChI Key: IPXDISVBOWEWKA-UHFFFAOYSA-N
Associated Targets(non-human)
Glutamate NMDA receptor; Grin1/Grin2c 1127 Activities
Ionotropic glutamate receptor NMDA 1/2D 870 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Glutamate NMDA receptor; Grin1/Grin2a 798 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Glutamate NMDA receptor; Grin1/Grin2b 1028 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 411.89 | Molecular Weight (Monoisotopic): 411.1350 | AlogP: 3.90 | #Rotatable Bonds: 5 |
| Polar Surface Area: 56.59 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 1.82 | CX LogP: 3.30 | CX LogD: 3.30 |
| Aromatic Rings: 3 | Heavy Atoms: 29 | QED Weighted: 0.64 | Np Likeness Score: -1.48 |
References
| 1. Epplin MP, Mohan A, Harris LD, Zhu Z, Strong KL, Bacsa J, Le P, Menaldino DS, Traynelis SF, Liotta DC.. (2020) Discovery of Dihydropyrrolo[1,2-a]pyrazin-3(4H)-one-Based Second-Generation GluN2C- and GluN2D-Selective Positive Allosteric Modulators (PAMs) of the N-Methyl-d-Aspartate (NMDA) Receptor., 63 (14): [PMID:32538088] [10.1021/acs.jmedchem.9b01733] |
Source
Source(1):